



Dr Harshal Deshmukh MRCP MPH PhD

NIHR Clinical Lecturer in Endocrinology and Diabetes

Dr Emma Wilmot
Dr Chris Walton
Dr Bob Ryder
Prof Thozhukat Sathyapalan





Disclosures

- EW has received personal fees from Abbott Diabetes Care, Dexcom, Diasend, Eli Lilly, Medtronic, Novo Nordisk, Sanofi Aventis
- Dr Bob Ryder has received speaker fees, and/or consultancy fees and/or educational sponsorships from AstraZeneca, BioQuest, GI Dynamics, Janssen, Novo Nordisk, Sanofi-Aventis and Takeda

Funding

The ABCD nationwide Freestyle Libre audit is supported by a grant from Abbott UK. The audit was independently initiated and performed by ABCD, and the authors remain independent in the analysis and preparation of this report.





- FreeStyle Libre is a flash glucose monitoring system which monitors interstitial glucose levels
- Consists of a sensor with a microfilament, worn on the back of the arm and a handheld reader
- When the reader unit is passed over the sensor, it shows the interstitial glucose levels
- The sensor lasts for 14 days, then needs to be replaced



The ABCD FSL Audit aims to explore the impact of the FSL on the following:

- HbA1c
- Hypoglycaemia awareness
- Resource utilisation: hospital admissions
- User satisfaction
- Diabetes related distress
- Discontinuation rate and causes



Methods





 Audit conducted in 70 hospitals in UK

 A <u>secure</u> IT tool was developed on the NHS computer network, N3, to make this process as easy and user friendly as possible



	tyle Libre Infor	mation Colle	otion Fe		Associates of British Chinal Statements
spital Name			Centre ID		
				Ethnicity	
te	/	/			British
ame of Clinician				White	Irish Any other white background
					Indian
mail				Asian or Asian British	Pakistani Bangladeshi
	AFFIX PATIENT LABEL HERE				Any other Asian background
IHS Number					Caribbean
				Black or Black British	African Any other
orename					White and black Caribbean
				Mixed	White Asian
Surname					Any other mixed background group Chinese
				Other ethnic group	Any other group
Date of Birth					Not stated
			Driving status	Does not drive Standard licence	
lender	Male	Female		Driving status	Taxi licence HGV licence
Height (m	ietres)	Weight (kg)		Body Mass Index	Duration of diabetes
					years
					months
Type of diabetes					
Type 1	Type 2		MODY		
During pregnance	cy: Gestati	ional diabetes	Type 1 d	labetes during pregnancy	Type 2 diabetes during pregnancy
Other (please	e specify)				
PATIENT USE O	F FREESTYLE LIBRE				
s this assessmen	t				
Recorded pri	for to commencing FreeS	Style Libre?		Recorded retrospec	tively - i.e. after FreeStyle Libre started?
	of FreeStyle Libre start?	(best estimate if ur	ncertain)	If not, intended date of	initiation of FreeStyle Libre
what is the date o	/	/		/	/
what is the date o	his the less & month had	ore starting FreeSt	yle Libre?	Funding of FreeStyle Li	bre
		No		NHS funded	Non-NHS funded
Jse of a CGM with		No		NHS funded	Non-NHS funded

Clinicians using FSL were the invited to submit the data that they routinely collect

Forms completed in clinic for later online submission or the online tool could be completed in real time



Results




Demographics and audit characteristics (n=3,382)

Age	34 (19-51)
Type 1 Diabetes	96%
Female (%)	54%
Duration of Diabetes (yrs)	14 (5-28)
BMI (kg/m2)	24 (21-28)
HbA1c (mmol/mol)	65 (56-76)
Median HbA1c readings at baseline	2 (1-4)
Median HbA1c readings at follow-up	2 (1-3)
Patients with at least 1 follow-up	715
Median follow-up (months)	6 (1-5)




Indications for FSL use in nation-wide FS udit





Effect on HbA1c (mmol/mol)






Median pre-FSL HbA1c (IQR)	65.7 (17.1)
Median post FSL HbA1c (IQR)	59 (16)
P-value*	<0.0001

*P-value from Mann-Whitney U Test






Median pre-FSL HbA1c (IQR)	80.1 (17)
Median post FSL HbA1c (IQR)	70 (17)
P-value*	<0.0001

*P-value from Mann-Whitney U Test




Effect on HbA1c in top contributing centres- and 👺 is stratified by centre








Effect on HbA1c in top contributing centres- anal in stratified by centre







Effect on Hypoglycaemia




Effect on Hypoglycaemia (GOLD Score*)



*Gold AE, MacLeod KM, Frier BM Diabetes Care 1994



Effect on awareness of hypoglycaemia (D Score)



	3.29
Median pre-FSL GOLD (IQR)	(1.85)
	2.79
Median post-treatment GOLD (IQR)	(1.91)
P-value	<0.0001

*P-value from Mann-Whitney U Test

More data needed to see if reversal of hypoglycaemia unawareness



- 78% reported that with use of FSL they were able to reduce the proportion of time in hypoglycaemia
- 33% able to reduce rate of hypoglycaemia
- 32% had reduced nocturnal hypoglycaemia



Effect on Hospital Admissions & Diabetes Diginess score

Median Follow-up period of 6 months

• In the 12 months prior to FSL initiation, 5% reported a hospital admission related to hyperglycaemia/diabetic ketoacidosis; at follow-up this was 1%



Diabetes distress score Discon Inuation

- Significant improvement in diabetes-related emotional score
- 3 (2-4) at baseline to 2 (1-3) at follow-up
 P<0.0001] in both components of brief DDSS
- 1% patie had discontinued using FSL at 6 month follow-up majority of them because of lack of funding





"Improved peace of mind"

"I find my freestyle libre invaluable due to my lifestyle and hill walking. For my sport I could be doing BG tests up to 15 times per day or more."

"We've had the libre for just over 2 years, it has completely transformed my sons diabetes care. He loves it! Gone are the painful finger pricks 12 times a day, gone are the nights of him being woken by a finger prick, now he can sleep through while I scan him"



Conclusions

FSL use associated with

- ✓ Significant improvement in HbA1c
- ✓ Significant improvement in Gold Score
- ✓ Possible reduction in hospital admissions due to DKA/H√p→ and Hyperglycaemia (1 year f/u data awaited)
- ✓ Improved diabetes related distress

Need for more follow-up data to see if beneficial effects are sustained



Acknowledgements

- Paties:
- Clinicians and support staff at the hospitals
- ABCD